The company has not filed an annual or quarterly report since its Q1 FY2019 10-Q, filed May 9, 2019. Its latest SEC filing is a SC 13G from Jul 29, 2019.
10-Q for Q1 FY2019, filed May 9, 2019
The sections below describe the company as of the FY2018 annual report.
Develops and sells medicines for dogs and cats, including treatments for post-operative pain, appetite loss and osteoarthritis, to companion-animal veterinarians.
10-K for FY2018, filed Mar 13, 2019
Veterinarians, clinics, animal hospitals and distributors pay for NOCITA and ENTYCE products. Elanco pays Aratana royalties on GALLIPRANT sales and milestone payments when specified sales or regulatory milestones are reached.
10-K for FY2018, filed Mar 13, 2019The Company generates product sales revenues primarily by selling its marketed therapeutics directly to end users (such as veterinarians…View ↗
· sales-based royalties from the Elanco Agreements consisting of a percentage of net sales of GALLIPRANT by Elanco that are recognized as…View ↗
· sales-based royalties from the Collaboration Agreement consisting of sales-based milestones of GALLIPRANT by Elanco that are recognized…View ↗
· regulatory milestones from the Collaboration Agreement that are recognized as revenue if and when achieved; andView ↗
$35.4M
10-K for FY2018, filed Mar 13, 2019
$35.4M ↗
Companion-animal veterinarians, clinics and animal hospitals buy products directly, while distributors also purchase products for resale. Elanco commercializes GALLIPRANT and pays related royalties and milestones.
10-K for FY2018, filed Mar 13, 2019The Company generates product sales revenues primarily by selling its marketed therapeutics directly to end users (such as veterinarians…View ↗
The Company generates licensing and collaboration revenue solely from the Elanco Collaboration, License, Development and Commercialization…View ↗
· sales-based royalties from the Elanco Agreements consisting of a percentage of net sales of GALLIPRANT by Elanco that are recognized as…View ↗
10-K for FY2018, filed Mar 13, 2019
Revenues from one customer, Elanco, accounted for all licensing and collaboration revenue for the years ended December 31, 2018 and 2017…View ↗
No. It lost $14.7M in FY2018.
10-K for FY2018, filed Mar 13, 2019
10-Q for Q1 FY2019, filed May 9, 2019
−$6.8MView ↗
8-K, filed Jul 18, 2019
On July 18, 2019, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) of the consummation of the Merger and requested that trading…View ↗
8-K, filed Apr 26, 2019
On April 26, 2019, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”), Elanco Athens Inc., a Delaware corporation and a…View ↗
Grew. Revenue grew 46.2x in 4 years, from $767K in FY2014 to $35.4M in FY2018, about 161% a year.
Competes with Zoetis, Merck Animal Health, Elanco, Bayer Animal Health, Boehringer Ingelheim Animal Health, Virbac Group, Ceva Animal Health, Vetoquinol, Dechra Pharmaceuticals, Kindred Biosciences, Zomedica Pharmaceuticals, VetDC, Skyline Vet Pharma, and Anivive
10-K for FY2018, filed Mar 13, 2019The development and commercialization of new animal health medicines is highly competitive, and we expect considerable competition from…View ↗
Loading...
